Sabirnetug (ACU193)Sabirnetug is the first immunotherapy drug candidate to enter the clinic that was developed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer’s by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function. |
||||
8-yearcollaboration with Merck |
$3.6 millionAwarded a competitive $3.6 million U01 grant from National Institute of |
IPO
|
||
Phase 1Enrollment Complete |
Phase 2Initiation 1H 2024 |
Phase 3Planning |
SubmissionPlanning |
ApprovalPlanning |
ALTITUDE-AD
This study is a Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous sabirnetug (ACU193) in Early Alzheimer’s Disease